Takara Bio Inc. Reports Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Six Months Ending September 30, 2017 and Year Ending March 31, 2018
July 26, 2017
Share
Takara Bio Inc. reported earnings results for the first quarter ended June 30, 2017. For the quarter, the company's net sales were ¥6,355 million against ¥6,306 million a year ago. Operating income was ¥262 million against ¥643 million a year ago. Ordinary income was ¥287 million against ¥653 million a year ago. Net income attributable to owners of the parent was ¥22 million against ¥285 million a year ago. Net income per share was ¥0.19 compared to ¥2.37 a year ago.
For the six months ending September 30, 2017, the company now expects net sales of ¥14,049 million, operating income of ¥487 million, ordinary income of ¥523 million, net income attributable to owners of the parent of ¥18 million or ¥0.16 per share.
For the year ending March 31, 2018, the company now expects net sales of ¥33,200 million, operating income of ¥3,300 million, ordinary income of ¥3,600 million, net income attributable to owners of the parent of ¥1,850 million or ¥15.36 per share.
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Takara Bio Inc. Reports Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Six Months Ending September 30, 2017 and Year Ending March 31, 2018